50 Days: How Foundayo Became the Fastest New Drug Approval Since 2002
The FDA approved orforglipron 50 days after filing and 294 days before its PDUFA date. The review timeline is a more consequential story than the drug itself.
Findings
- The FDA approved Foundayo (orforglipron) on April 1, 2026, 50 days after filing.
- The decision came 294 days before the application's PDUFA date of January 20, 2027.
- It is the fastest approval of a new molecular entity since 2002, and the first NME approved under the Commissioner's National Priority Voucher pilot program.
- The agency attributes the speed to reduced idle time and continuous sponsor-agency communication rather than to any reduction in evidentiary standard.
Review timeline
The dates, in order
- Late 2025FDA accepts the new drug application for orforglipron for chronic weight management in adults with obesity or overweight with weight-related comorbidities.
- March 2026An FDA decision had initially been anticipated in March; the agency extends the review target to April 10 while continuing evaluation under the enhanced CNPV program.
- March 25, 2026Sponsor submits the postmarketing study timetable referenced in the approval letter.
- April 1, 2026FDA approves Foundayo — ahead of the adjusted April 10 target and 294 days before the January 20, 2027 PDUFA date.
What the agency says produced the speed
The FDA's account emphasises process rather than standard. The approval was made under the Commissioner's National Priority Voucher pilot pathway, with the agency describing accelerated review achieved through reduced idle time and continuous communication between sponsor and agency. FDA Commissioner Martin Makary framed the decision as a demonstration of what the agency can achieve when delays are eliminated and both the agency and industry partners work quickly and thoroughly.
Idle time is the operative concept. A standard review clock includes long intervals in which an application sits in a queue rather than being actively examined. Compressing those intervals shortens the calendar without necessarily shortening the substantive review.
A fast approval is not evidence of a weak review, and it is not evidence of a strong drug. It is evidence about queue management. The substantive question — whether the ATTAIN data supported approval — is answered by the trials, not by the calendar.
Why this timeline is worth tracking
Foundayo is the first new molecular entity approved under the CNPV pilot, which makes it the precedent case. Every subsequent argument about whether the program compresses timelines safely will cite this file. That is a heavier burden than any single product approval normally carries.
The FDA has treated the program as provisional rather than settled. The agency scheduled a public meeting on June 4, 2026, rescheduled from June 12, to solicit feedback on the program's eligibility criteria, the voucher selection process, sponsor responsibilities, pre-submission requirements, review procedures, the role of the CNPV review council, and implementation generally. Written comments were accepted through June 29, 2026.
- Whether the compressed timeline affected the depth of any specific review element.
- How the postmarketing requirement package compares in scope to what a standard-timeline review would have produced.
- What the June 2026 comment record concluded, and whether eligibility criteria were revised as a result.
- Whether subsequent CNPV approvals sustain the same timeline compression.
The postmarketing tradeoff
One structural feature of accelerated review is that questions not fully resolved before approval get moved into postmarketing requirements. The Foundayo approval letter reflects this. It includes a requirement for a medullary thyroid carcinoma registry-based case series of at least 15 years duration to monitor annual incidence in the United States and identify any increase related to the drug's market introduction, with study completion estimated for September 2034 and a final report due September 2035. A separate required study addresses delayed gastric emptying and pulmonary aspiration risk.
That is the honest accounting of an accelerated approval: the drug reaches patients sooner, and some of the safety characterisation happens afterward, in the population rather than in a trial.
Primary sources & citations
- US Food and Drug Administration, “FDA Approves First New Molecular Entity Under National Priority Voucher Program,” April 1, 2026.
- FDA approval letter for NDA 220934, Foundayo (orforglipron) tablets, including postmarketing requirements and submitted timetables.
- MedCentral, reporting on the PDUFA date extension and CNPV review process.
- Pharmacy Times, coverage of the CNPV pilot pathway and review approach.
- FDA notice of public meeting on the CNPV program, June 4, 2026, with written comments accepted through June 29, 2026.
Editorial note
Looking for a provider rather than a citation?
This site does not review or rank telehealth providers inside its research articles, and carries no provider links in article text. Our provider comparison grid, including how each one is monetized, lives on the homepage.
Open the provider grid